PCRX Logo

Pacira BioSciences, Inc. (PCRX) 

NASDAQ
Market Cap
$895.76M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
232 of 960
Rank in Industry
11 of 59

Largest Insider Buys in Sector

PCRX Stock Price History Chart

PCRX Stock Performance

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that …

Insider Activity of Pacira BioSciences, Inc.

Over the last 12 months, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $4.29M worth of Pacira BioSciences, Inc. stock.

On average, over the past 5 years, insiders at Pacira BioSciences, Inc. have bought $153,467 and sold $17.34M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lee Frank D. (Chief Executive Officer) — $99,994. BIGAL MARCELO (director) — $60,868. YANG MICHAEL J. (director) — $51,600.

The last purchase of 1,512 shares for transaction amount of $20,034 was made by BIGAL MARCELO (director) on 2024‑08‑16.

List of Insider Buy and Sell Transactions, Pacira BioSciences, Inc.

2024-12-13SaleChief Operating Officer
500
0.0011%
$19.76$9,880-0.15%
2024-09-13SaleChief Operating Officer
500
0.0011%
$12.86$6,430+27.99%
2024-08-16Purchasedirector
1,000
0.0023%
$12.81$12,810+9.13%
2024-08-16Purchasedirector
1,512
0.0036%
$13.25$20,034+5.51%
2024-08-14Purchasedirector
2,000
0.0046%
$12.90$25,8000.00%
2024-08-12PurchaseChief Executive Officer
8,264
0.0178%
$12.10$99,994+33.85%
2024-08-12Purchasedirector
1,400
0.0029%
$11.58$16,212+33.85%
2024-08-12Purchasedirector
3,400
0.0073%
$12.01$40,834+33.85%
2024-08-02SaleChief Medical Officer
945
0.0019%
$20.05$18,947-22.30%
2024-07-02SaleChief Medical Officer
2,836
0.0062%
$28.25$80,1170.00%
2024-06-13SaleChief Operating Officer
1,000
0.0021%
$28.38$28,380-40.78%
2024-06-13SaleChief Administrative Officer
7,452
0.0157%
$28.38$211,488-40.78%
2024-06-13Saledirector
880
0.0019%
$28.38$24,974-40.78%
2024-06-12SaleSenior Vice President, Finance
3,970
0.0085%
$28.72$114,018-41.30%
2024-06-11SaleChief Medical Officer
5,012
0.0106%
$28.57$143,193-41.77%
2024-03-08Saledirector
90,000
0.1889%
$30.60$2.75M-34.54%
2024-03-07Saledirector
28,257
0.0613%
$30.81$870,598-32.30%
2024-03-06Saledirector
1,066
0.0023%
$29.67$31,628-30.66%
2023-08-02SaleChief Medical Officer
509
0.0011%
$34.88$17,751-19.01%
2023-07-05SaleSenior Vice President, Finance
643
0.0014%
$38.91$25,019-22.50%

Insider Historical Profitability

22.98%
Lee Frank D.Chief Executive Officer
107784
0.2334%
$19.4010
PACE GARY Wdirector
22127
0.0479%
$19.4056+11.64%
Brege Lauradirector
17552
0.038%
$19.4016
Froimson Markdirector
14473
0.0313%
$19.4022<0.0001%
HASTINGS PAUL Jdirector
12724
0.0276%
$19.40118+79.52%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$230.99M16.987.91M-2.58%-$6.11M0.01
The Vanguard Group$149.41M10.995.11M+0.29%+$437,131.20<0.01
Frontier Capital Management Co$55.94M4.111.91M-8.16%-$4.97M0.52
State Street$55.62M4.091.9M-1.68%-$950,994.13<0.01
Renaissance Technologies$55M4.041.88M+9.64%+$4.84M0.09
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.